Business Description
Appili Therapeutics Inc
NAICS : 325410
SIC : 3741
ISIN : CA03783R1073
Share Class Description:
APLIF: Ordinary SharesTotal Employee Number:
9Description
Appili Therapeutics Inc is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes programs namely ATI-1701, ATI-1801.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.02 | |||||
Equity-to-Asset | -29.9 | |||||
Debt-to-Equity | -0.76 | |||||
Debt-to-EBITDA | -8.69 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -234.5 | |||||
Beneish M-Score | -45.74 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -63.8 | |||||
3-Year EPS without NRI Growth Rate | 63.8 | |||||
3-Year Book Growth Rate | -33.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 52 | |||||
9-Day RSI | 50.11 | |||||
14-Day RSI | 49.08 | |||||
3-1 Month Momentum % | -5.36 | |||||
6-1 Month Momentum % | -28.86 | |||||
12-1 Month Momentum % | 0.95 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.03 | |||||
Quick Ratio | 0.03 | |||||
Cash Ratio | 0.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -19.4 | |||||
Shareholder Yield % | -121.91 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -1416.51 | |||||
Net Margin % | -1437.38 | |||||
EBITDA Margin % | -696.12 | |||||
FCF Margin % | -24.16 | |||||
OCF Margin % | -24.16 | |||||
ROA % | -177.75 | |||||
ROIC % | -25.55 | |||||
3-Year ROIIC % | 206.91 | |||||
ROC (Joel Greenblatt) % | -9031.25 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 8.15 | |||||
Price-to-Free-Cash-Flow | 16.3 | |||||
Price-to-Operating-Cash-Flow | 16.3 | |||||
EV-to-EBIT | -9.26 | |||||
EV-to-EBITDA | -9.33 | |||||
EV-to-Revenue | 66.94 | |||||
EV-to-Forward-Revenue | 0.62 | |||||
EV-to-FCF | -277.06 | |||||
Price-to-GF-Value | 1.13 | |||||
Earnings Yield (Greenblatt) % | -10.8 | |||||
FCF Yield % | -2.66 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:APLIF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Appili Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.149 | ||
| EPS (TTM) ($) | -0.021 | ||
| Beta | 0.1336 | ||
| 3-Year Sharpe Ratio | -0.05 | ||
| 3-Year Sortino Ratio | -0.1 | ||
| Volatility % | 65.81 | ||
| 14-Day RSI | 49.08 | ||
| 14-Day ATR ($) | 0.00174 | ||
| 20-Day SMA ($) | 0.011229 | ||
| 12-1 Month Momentum % | 0.95 | ||
| 52-Week Range ($) | 0.00804 - 0.0309 | ||
| Shares Outstanding (Mil) | 128.37 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Appili Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Appili Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2027 | 2026-11-13 | In 140 days | ||
| General meeting for 2026 | 2026-09-23 11:00 | In 90 days | ||
| First quarter earnings results for 2027 | 2026-08-14 | In 49 days | ||
| Annual report for 2026 | 2026-06-25 | 0.01 (+0.00%) | ||
| Third quarter earnings results for 2026 | 2026-02-12 | 0.02 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2025-11-13 | 0.02 (-6.10%) | ||
| General meeting for 2025 | 2025-09-23 11:00 | 0.01 (+30.77%) | ||
| First quarter earnings results for 2026 | 2025-08-14 | 0.01 (+0.00%) | ||
| Annual report for 2025 | 2025-06-25 | 0.01 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-02-14 | 0.02 (+0.00%) |
Show
Entries
Appili Therapeutics Inc Frequently Asked Questions
What is Appili Therapeutics Inc(APLIF)'s stock price today?
The current price of APLIF is $0.01. The 52 week high of APLIF is $0.03 and 52 week low is $0.01.
When is next earnings date of Appili Therapeutics Inc(APLIF)?
The next earnings date of Appili Therapeutics Inc(APLIF) is 2026-08-14 Est..
Does Appili Therapeutics Inc(APLIF) pay dividends? If so, how much?
Appili Therapeutics Inc(APLIF) does not pay dividend.
Guru Commentaries on OTCPK:APLIF
No articles.
Press Release
Articles on Appili Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers